Guillain-Barré syndrome
详细信息 查看全文
- 作者：Satoshi Kuwabara MD (1)
- 刊名：Current Neurology and Neuroscience Reports
- 出版年：2007
- 出版时间：January 2007
- 年：2007
- 卷：7
- 期：1
- 页码：57-62
- 全文大小：160KB
- 参考文献：1. Griffin JW, Li CY, Ho TW, et al.: Pathology of the motorsensory axonal Guillain-Barré syndrome. / Ann Neurol 1996, 39:17-8. CrossRef
2. Kuwabara S: Guillain-Barré syndrome. Epidemiology, pathophysiology and management. / Drugs 2004, 64:597-10. CrossRef
3. Hughes RA, Corblath DR: Guillain-Barré syndrome. / Lancet 2005, 366:1653-666. CrossRef
4. Ho TW, Mishu B, Li CY, et al.: Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. / Brain 1995, 118:597-05. CrossRef
5. Ogawara K, Kuwabara S, Mori M, et al.: Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. / Ann Neurol 2000, 48:624-31. CrossRef
6. Yuki N: Carbonhydrate mimicry: a new paradigm of autoimmune diseases. / Curr Opin Immunol 2005, 17:577-82. CrossRef
7. Hadden RD, Cornblath DR, Hughes RA, et al.: Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. / Ann Neurol 1998, 44:780-88. CrossRef
8. Jacobs BC, Rothbarth PH, van der Meché FG, et al.: The spectrum of antecedent infections in Guillain-Barré syndrome. A case control study. / Neurology 1998, 51:1110-115.
9. Hughes RA, Rees JH: Clinical and epidemiologic features of Guillain-Barré syndrome. / J Infect Dis 1997, 175(Suppl): S92–S100.
10. Kuwabara S, Ogawara K, Misawa S, et al.: Does Campylobacter jejuni infection elicit “demyelinating-Guillain-Barré syndrome? / Neurology 2004, 63:529-33.
11. Yuki N, Susuki K, Koga M, et al.: Carbonhydrate mimicry between human ganglioside GM1 asnd Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. / Proc Natl Acad Sci USA 2004, 101:11404-1409. CrossRef
12. Yuki N, Yamada M, Koga M, et al.: Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. / Ann Neurol 2001, 49:712-20. CrossRef
13. Susuki K, Nishimoto Y, Yamada M, et al.: Acute motor axonal neuropathy rabbit model: immune attack on nerve root axons. / Ann Neurol 2003, 54:383-88. CrossRef
14. Gilbert M, Karwaski MF, Bernatchez S, et al.: The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni: biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. / J Biol Chem 2002, 277:327-37. CrossRef
15. Godschalk PC, Heikema AP, Gilbert M, et al.: The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barré syndrome. / J Clin Invest 2004, 14:1659-665. CrossRef
16. Koga M, Takahashi M, Masuda M, et al.: Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. / Neurology 2005, 65:1376-381. CrossRef
17. Olsson Y: Microenvironment of the peripheral nervous system under normal and pathological conditions. / Crit Rev Neurobiol 1990, 5:265-11.
18. Bromberg M, Albers JW: Patterns of sensory nerve conduction abnormalities in demyelinating anad axonal peripheral nerve disorders. / Muscle Nerve 1993, 16:262-66. CrossRef
19. Kuwabara S, Ogawara K, Misawa S, et al.: Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy. / J Neurol Neurosurg Psychiatry 2002, 72:37-2. CrossRef
20. Kuwabara S, Ogawara K, Misawa S, et al.: Sensory nerve conduction in demyelinating and axonal Guillain-Barré syndromes. / Eur Neurol 2004, 51:196-98. CrossRef
21. Kuwabara S, Yuki N, Koga M, et al.: IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. / Ann Neurol 1998, 44:202-08. CrossRef
22. Hiraga A, Kuwabara S, Ogawara K, et al.: Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barré syndrome. / Neurology 2005, 64:856-60.
23. Kuwabara S, Ogawara K, Sung JY, et al.: Differences in membrane properties of axonal and demyelinating Guillain-Barré syndromes. / Ann Neurol 2002, 52:180-87. CrossRef
24. Kuwabara S, Bostock H, Ogawara K, et al.: The refractory period of transmission is impaired in axonal Guillain-Barré syndrome. / Muscle Nerve 2003, 28:683-89. CrossRef
25. Kiernan MC, Isbister GK, Lin CS, et al.: Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. / Ann Neurol 2005, 57:339-48. CrossRef
26. Pedraza L, Huang J, Colman DR: Organizing principles of the axoglial apparatus. / Neuron 2001, 30:335-44. CrossRef
27. Melendez-Vasquez CV, Rios J, Zanazzi G, et al.: Nodes of Ranvier form in association with ezrin-radixin-moesin (ERM)-positive Schwann cell processes. / Proc Natl Acad Sci U S A 2001, 98:1235-240. CrossRef
28. Ishubashi T, Dupree JL, Ikenaka K, et al.: A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation. / J Neurosci 2002, 22:6507-514.
29. Hughes RA, Swan AV, van Koningsveld R, et al.: Corticosteroids for Guillain-Barré syndrome. / Cochrane Database Syst Rev 2006, 19:CD001446.
30. Rich MM, Pinter MJ: Sodium channel inactivation in an animal model of acute quadriplegic myopathy. / Ann Neurol 2001, 50:26-3. CrossRef
31. Raphael JC, Chevret S, Hughes RA, et al.: Plasma exchange for Guillain-Barré syndrome. / Cochrane Database Syst Rev 2001, CD001798.
32. Hughes RA, Raphael JC, Swan AV, et al.: Intravenous immunoglobulin for Guillain-Barré syndrome. / Cochrane Database Syst Rev 2004, CD002063.
33. Hadden RD, Karch H, Hartung HP, et al.: Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. / Neurology 2001, 56:758-65.
34. Kuwabara S, Mori M, Ogawara K, et al.: Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody. / Muscle Nerve 2001, 24:54-8. CrossRef
35. Wollinsky KH, Hulser PJ, Brinkmeier H, et al.: CFS filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. / Neurology 2002, 57:774-80.
36. Schaller B, Radziwill AJ, Steck AJ: Successful treatment of Guillain-Barré syndrome with combined administration of Interferon-b-1a and intravenous immunoglobulin. / Eur Neurol 2001, 46:167-68. CrossRef
37. Miyamoto K, Oka N, Kawasaki T, et al.: New cyclooxygenase-2-inhibitors for treatment of experimental autoimmune neuritis. / Muscle Nerve 2002, 25:280-82. CrossRef
38. Bechtold DA, Yue X, Evans RM, et al.: Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecanamide. / Brain 2005, 128:18-8. CrossRef
39. Rees JH, Thompson RD, Smeeton NC, et al.: Epidemiological study of Guillain-Barré syndrome in south east England. / J Neurol Neurosurg Psychiatry 1998, 64:74-7. CrossRef - 作者单位：Satoshi Kuwabara MD (1)
1. Department of Neurology, Chiba University School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan
文摘
Guillain-Barré syndrome (GBS) is currently divided into the two major subtypes: acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN). This review highlights relevant recent publications, particularly on the pathophysiology of AMAN. Molecular mimicry of the bacterial lipo-oligosaccharide by the human gangliosides is now considered an important cause of AMAN. Gangliosides GM1, GM1b, GD1a, and GalNAc-GD1a expressed on the motor axolemma are likely to be the epitopes for antibodies in AMAN. At the nodes or paranodes, deposition of antiganglioside antibodies initially cause reversible conduction block followed by axonal degeneration. Electrodiagnostic findings support this process. Disruption of glycolipids, which are important to maintain ion channel clustering at the nodes and paranode, may impair nerve conduction. Genetic polymorphisms of Campylobacter jejuni determine the expression of the gangliosides on the bacterial wall. In contrast, target molecules in AIDP have not yet been identified. Meta-analyses show efficacy of plasmapheresis and immunoglobulin therapy, but not corticosteroids, in hastening recovery.